Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
7.65
-0.48 (-5.90%)
Aug 8, 2025, 3:56 PM - Market open

Acelyrin Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
4714850415061,054
Upgrade
Market Cap Growth
61.27%197.20%21.95%-91.94%-52.00%-
Upgrade
Enterprise Value
-6682-9-882761,180
Upgrade
Last Close Price
8.1339.8416.6023.82296.75691.25
Upgrade
PS Ratio
20.0637.483.202.93116.05-
Upgrade
PB Ratio
0.49-5.100.540.392.744.79
Upgrade
P/TBV Ratio
0.49-0.540.392.744.79
Upgrade
EV/Sales Ratio
-20.81--63.34-
Upgrade
Debt / Equity Ratio
0.07-0.290.120.120.080.06
Upgrade
Asset Turnover
0.030.040.100.070.02-
Upgrade
Quick Ratio
6.072.625.683.804.908.04
Upgrade
Current Ratio
6.312.865.904.035.258.26
Upgrade
Return on Equity (ROE)
-87.74%-415.84%-89.48%-66.55%-63.41%-64.37%
Upgrade
Return on Assets (ROA)
-40.30%-50.29%-36.63%-31.92%-32.04%-29.70%
Upgrade
Return on Capital (ROIC)
-52.81%-134.89%-49.73%-38.64%-37.11%-33.55%
Upgrade
Earnings Yield
-148.34%-88.73%-176.22%-235.41%-25.37%-10.30%
Upgrade
FCF Yield
-150.21%-54.69%-158.81%-196.90%-23.04%-7.24%
Upgrade
Buyback Yield / Dilution
-62.20%-144.38%-50.10%-7.12%-299.03%-397.63%
Upgrade
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q